Compare VSAT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | GRFS |
|---|---|---|
| Founded | 1986 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.2B |
| IPO Year | 1996 | 2006 |
| Metric | VSAT | GRFS |
|---|---|---|
| Price | $41.60 | $9.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $37.20 | $10.15 |
| AVG Volume (30 Days) | ★ 1.9M | 472.1K |
| Earning Date | 02-05-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | $4,616,074,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $5.25 | $5.36 |
| Revenue Next Year | $3.45 | $5.15 |
| P/E Ratio | ★ N/A | $17.88 |
| Revenue Growth | 2.07 | ★ 7.31 |
| 52 Week Low | $7.36 | $6.19 |
| 52 Week High | $49.68 | $11.14 |
| Indicator | VSAT | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 48.88 |
| Support Level | $36.71 | $9.23 |
| Resistance Level | $49.68 | $9.60 |
| Average True Range (ATR) | 3.02 | 0.19 |
| MACD | -0.80 | 0.00 |
| Stochastic Oscillator | 38.78 | 53.61 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.